Roche Licenses Simcere’s Tri-Specific Antibody SIM0660
Nanjing, China, September 1, 2026 Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, has entered into an exclusive global...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Nanjing, China, September 1, 2026 Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, has entered into an exclusive global...
Dallas, Texas, September 1, 2026 Cizzle Bio, Inc. has announced the publication of a new peer-reviewed study providing additional...
